Ecallantide (Kalbitor)

Covered: Ecallantide (Kalbitor) is approved for acute hereditary angioedema (HAE) attacks in patients ≥12 years with HAE confirmed by low C4 and low C1 inhibitor antigenic/functional levels and when the request is specifically for an acute attack. Key requirements: administration must be by a healthcare professional in a setting equipped to manage anaphylaxis, concurrent use with other acute HAE agents (e.g., Berinert, Firazyr, Ruconest) is prohibited, documentation of diagnosis, age, acute-attack indication, administration setting, and non‑concurrent therapy is required, and no off‑label compendial uses are approved.

"Kalbitor is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older."

Sign up to see full coverage criteria, indications, and limitations.